Research reportDecreased Mcl-1 protein level in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice
-
Add time:09/07/2019 Source:sciencedirect.com
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a well-known neurotoxicant that can selectively destroy dopaminergic neurons and MPTP-treated animals are often used as models for studying aspects of Parkinson’s disease (PD). While apoptosis has been suggested as a possible mechanism underlying MPTP-induced cell death and several apoptosis-associated proteins have been implicated in MPTP-animal models, relevant information regarding the possible involvement of Mcl-1 (myeloid cell leukemia 1) protein is missing. Mcl-l is an important member of the Bcl-2 family that is thought to be a highly regulated controller of cell death and survival. However, the expression level of Mcl-1 in response to MPTP-treatment has not been examined in any area of the brain previously. In the present study, an acute MPTP treatment regimen was utilized with male C57BL/6 mice (10 mg/kg i.p. injections, 4 times with 2 h intervals) and several protein markers were examined 24-h after the initial injection. Dramatic decreases in the immunoreactivities of tyrosine hydroxylase and dopamine transporters were observed. Western-blot analysis and immunocytochemical labeling demonstrated an MPTP-induced decrease in Mcl-1 protein levels in the striatum. In addition, the two proteins BAX and ERK, both of which are also involved in apoptosis signaling, were examined. While the total BAX levels showed no significant difference between the control and MPTP-treated groups, levels of phosphorylated ERK were significantly increased following MPTP-treatment. Since Mcl-1 is an anti-apoptotic protein, down-regulation of Mcl-1 following MPTP-treatment would be expected to lead to increased apoptotic activities processes, leading to increased neurodegeneration.
We also recommend Trading Suppliers and Manufacturers of 1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE (cas 18513-79-6). Pls Click Website Link as below: cas 18513-79-6 suppliers
Prev:1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice
Next:Expedient synthesis of 3-substituted-1,2,3,6-tetrahydropyridines) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-TETRAHYDROPYRIDINE HYDROCHLORIDE (cas 18513-79-6) treated marmoset with the melatonin analogue ML-2309/27/2019
- Research ArticleMulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model09/26/2019
- Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: A search for novel nitric oxide donor anti-inflammatory agents09/25/2019
- Chapter 91 - The Neuropathology of Movement Disorders in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and Methcathinone (Ephedrone) Addictions09/24/2019
- Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT2C agonists09/10/2019
- 4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors09/09/2019
- Expedient synthesis of 3-substituted-1,2,3,6-tetrahydropyridines09/08/2019
- 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice09/06/2019
- Original articleEXPERIMENTAL STUDY OF ANTIPARKINSONIAN ACTION OF THE HARMINE HYDROCHLORIDE ORIGINAL COMPOUND09/05/2019
-
Health and Chemical more >
-
Related Products


